Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Higher Morbidity and Mortality in Women With Fournier Gangrene Compared With Men: Insights From National Inpatient Sample Data.
The Journal of Urology ( IF 5.9 ) Pub Date : 2024-10-02 , DOI: 10.1097/ju.0000000000004264 Behzad Abbasi,Emily Hacker,Umar Ghaffar,Nizar Hakam,Kevin D Li,Sultan Alazzawi,Adrian Fernandez,Hiren V Patel,Benjamin N Breyer
The Journal of Urology ( IF 5.9 ) Pub Date : 2024-10-02 , DOI: 10.1097/ju.0000000000004264 Behzad Abbasi,Emily Hacker,Umar Ghaffar,Nizar Hakam,Kevin D Li,Sultan Alazzawi,Adrian Fernandez,Hiren V Patel,Benjamin N Breyer
PURPOSE
To compare Fournier gangrene in female and male patients and identify mortality-associated characteristics in both.
MATERIALS AND METHODS
We used National Inpatient Sample data (2016-2020) to identify Fournier gangrene cases and extracted demographic, comorbidity, and procedural variables. Multivariable regression models were used to identify mortality risk factors for both cohorts.
RESULTS
We identified 2875 female (31%) and 6451 male patients (69%) with Fournier gangrene corresponding to an estimated 14,375 (95% CI, 13,784-14,966) and 32,255 (95% CI, 31,390-33,120) cases, respectively. Female patients were more likely to die than male patients (7.1% vs 5.7%, P < .0001, respectively). The median incidence rates were 1.7 (IQR, 1.5-1.8) and 4 (IQR, 3.6-4.3) cases per 100,000 person-years for female and male patients, respectively. Female patients had higher median age, longer hospital stays, more charges, procedures, and fecal diversion rates, but lower routine discharges than male patients (P < .05). Non-White female patients had increased mortality odds compared with White female patients (odds ratio [OR], 1.49; 95% CI, 1.07-2.07; P = .019). Prolonged interval until initial perineal debridement correlated with higher mortality odds in both female and male patients (OR, 1.02; 95% CI, 1-1.04; P = .034 vs OR, 1.03; 95% CI, 1.01-1.05; P < .0001). Diabetes lowered mortality odds in female and male patients (OR, 0.68; 95% CI, 0.47-0.99; P = .046 vs OR, 0.54; 95% CI, 0.41-0.7; P < .0001).
CONCLUSIONS
In female patients, Fournier gangrene incidence surpasses previous reports, with slightly worse outcomes compared with male patients, emphasizing the need for precise clinical assessment and early intensive interventions.
中文翻译:
与男性相比,患有 Fournier 坏疽的女性发病率和死亡率更高:来自全国住院样本数据的见解。
目的 比较女性和男性患者的 Fournier 坏疽,并确定两者的死亡率相关特征。材料和方法 我们使用全国住院样本数据 (2016-2020) 来确定 Fournier 坏疽病例并提取人口统计学、合并症和程序变量。使用多变量回归模型来确定两个队列的死亡风险因素。结果 我们确定了 2875 例女性 (31%) 和 6451 例男性 (69%) 患有 Fournier 坏疽的患者,分别对应于估计的 14,375 例 (95% CI,13,784-14,966) 例和 32,255 例 (95% CI,31,390-33,120) 例。女性患者比男性患者更容易死亡 (分别为 7.1% 和 5.7%,P < .0001)。女性和男性患者的中位发病率分别为 1.7 例 (IQR,1.5-1.8) 和 4 例 (IQR,3.6-4.3) 例/100,000 人年。与男性患者相比,女性患者的中位年龄较高,住院时间更长,费用、手术和粪便分流率更高,但常规出院率较低 (P < .05)。与白人女性患者相比,非白人女性患者的死亡率比值增加(比值比 [OR],1.49;95% CI,1.07-2.07;P = .019)。在女性和男性患者中,延长至初始会阴清创术的间隔与较高的死亡率相关 (OR,1.02;95% CI,1-1.04;P = .034 vs OR,1.03;95% CI,1.01-1.05;P < .0001).糖尿病降低了女性和男性患者的死亡率 (OR,0.68;95% CI,0.47-0.99;P = .046 vs OR,0.54;95% CI,0.41-0.7;P < .0001).结论 在女性患者中,Fournier 坏疽发生率超过既往报道,与男性患者相比,预后略差,强调需要精确的临床评估和早期强化干预。
更新日期:2024-10-02
中文翻译:
与男性相比,患有 Fournier 坏疽的女性发病率和死亡率更高:来自全国住院样本数据的见解。
目的 比较女性和男性患者的 Fournier 坏疽,并确定两者的死亡率相关特征。材料和方法 我们使用全国住院样本数据 (2016-2020) 来确定 Fournier 坏疽病例并提取人口统计学、合并症和程序变量。使用多变量回归模型来确定两个队列的死亡风险因素。结果 我们确定了 2875 例女性 (31%) 和 6451 例男性 (69%) 患有 Fournier 坏疽的患者,分别对应于估计的 14,375 例 (95% CI,13,784-14,966) 例和 32,255 例 (95% CI,31,390-33,120) 例。女性患者比男性患者更容易死亡 (分别为 7.1% 和 5.7%,P < .0001)。女性和男性患者的中位发病率分别为 1.7 例 (IQR,1.5-1.8) 和 4 例 (IQR,3.6-4.3) 例/100,000 人年。与男性患者相比,女性患者的中位年龄较高,住院时间更长,费用、手术和粪便分流率更高,但常规出院率较低 (P < .05)。与白人女性患者相比,非白人女性患者的死亡率比值增加(比值比 [OR],1.49;95% CI,1.07-2.07;P = .019)。在女性和男性患者中,延长至初始会阴清创术的间隔与较高的死亡率相关 (OR,1.02;95% CI,1-1.04;P = .034 vs OR,1.03;95% CI,1.01-1.05;P < .0001).糖尿病降低了女性和男性患者的死亡率 (OR,0.68;95% CI,0.47-0.99;P = .046 vs OR,0.54;95% CI,0.41-0.7;P < .0001).结论 在女性患者中,Fournier 坏疽发生率超过既往报道,与男性患者相比,预后略差,强调需要精确的临床评估和早期强化干预。